Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

ConclusionDupilumab improved AD signs and symptoms in patients aged ≥ 60 years; results were comparable to those in patients aged< 60 years. Safety was consistent with the known dupilumab safety profile.Trial RegistrationClinicalTrials.gov: NCT02277743, NCT02277769, NCT02755649, NCT02260986.Graphical abstractVideo abstractDoes dupilumab benefit adults aged 60 years and older with moderate-to-severe atopic dermatitis?(MP4 20,787 KB)

http://link.springer.com/10.1007/s40257-022-00754-4

Source: American Journal of Clinical Dermatology - February 20, 2023 Category: Dermatology Source Type: research